Anika Therapeutics (ANIK) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 Revenue Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 -1.05%
EPS Growth %: -25.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -25.0%
Financial Fact:
Income from operations: 13.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.17, $0.10 better than the analyst estimate of $0.07. Revenue for the quarter came in at $41.9 million versus the consensus estimate of $40.77 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.8 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- InMed Pharmaceuticals gets Nasdaq equity deficiency notice
- RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
